General Information of Drug (ID: DML4ZOT)

Drug Name
Lidocaine Drug Info
Synonyms
Alphacaine; Anestacon; Cappicaine; Cuivasil; Dalcaine; Dentipatch; DermaFlex; Dilocaine; Duncaine; EMBOLEX; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; LIDOPEN; LQZ; Lanabiotic; Leostesin; Lidocaina; Lidocainum; Lidocaton; Lidoderm; Lignocaine; Lignocainum; Lingocaine; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Xilocaina; Xllina; Xycaine; Xylestesin; Xylesthesin; Xylocain; Xylocaine; Xylocard; Xylocitin; Xylotox; Zingo; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Anestacon Jelly; Cito optadren; Emla Cream; Lidocaine Carbonate; Lidocaine Hydrocarbonate; Lidocaine Monohydrochloride; Norwood Sunburn Spray; Rocephin Kit; Solarcaine aloe extraburn relief cream; Xilocaina [Italian]; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; CDS1_000283; L1026_SIGMA; Xylocaine CO2; Dentipatch (TN); ELA-Max; L-Caine; Lida-Mantle; Lidocaina [INN-Spanish]; Lidocaine (VAN); Lidocainum [INN-Latin]; Lidoject-1; Lidoject-2; Octocaine-100; Octocaine-50; Xylocaine (TN); Xylocaine 5% Spinal; Xylocaine-Mpf; Xylocaine-Mpf with Glucose; Xyloneural (free base); Zilactin-L; Lidocaine [USAN:INN:JAN]; Diethylaminoaceto-2,6-xylidide; Lidocaine (JP15/USP/INN); Alfa-Dietilamino-2,6-dimetilacetanilide; Alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Alpha-Diethylamino-2,6-dimethylacetanilide; Alpha-Diethylaminoaceto-2,6-xylidide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); Omega-Diethylamino-2,6-dimethylacetanilide; Alpha-(Diethylamino)-2,6-acetoxylidide; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
Indication
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [1]
Carpal tunnel syndrome Approved [2]
Interstitial cystitis GC00.3 Approved [2]
Long QT syndrome BC65.0 Approved [2]
Pain MG30-MG3Z Approved [2]
Pediculus capitis infestation 1G00.0 Approved [2]
Periodontitis DA0C Approved [2]
Postherpetic neuralgia 1E91.5 Approved [2]
Pthirus pubis infestation Approved [2]
Dysmenorrhea GA34.3 Phase 2 [3]
Chronic pain MG30 Investigative [2]
Neuralgia Investigative [2]
Premature ejaculation HA03.0Z Investigative [2]
Pruritus EC90 Investigative [2]
Therapeutic Class
Anesthetics
Cross-matching ID
PubChem CID
3676
ChEBI ID
CHEBI:6456
CAS Number
CAS 137-58-6
TTD Drug ID
DML4ZOT
VARIDT Drug ID
DR00849
INTEDE Drug ID
DR0953

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [18]
Lacosamide DMVM6QR Convulsion 8A68.Z Approved [19]
Riluzole DMECBWN Amyotrophic lateral sclerosis 8B60.0 Approved [20]
Tolperisone DMA2GHJ Muscle spasm MB47.3 Approved [21]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [22]
Eslicarbazepine DMZREFQ Seizure disorder 8A6Z Approved [19]
Oxcarbazepine DM5PU6O Epilepsy 8A60-8A68 Approved [23]
HP-184 DMNOMV2 Multiple sclerosis 8A40 Phase 2 [24]
QX-314 DMAV2FM Pain MG30-MG3Z Terminated [25]
PD-32577 DMBA15J Discovery agent N.A. Investigative [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [27]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [28]
Methotrexate DM2TEOL Anterior urethra cancer Approved [5]
Folic Acid DMEMBJC Colorectal carcinoma Approved [29]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [5]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [5]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [30]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [5]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [31]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [33]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [34]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [35]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [36]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [37]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [38]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [39]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [40]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [34]
Verapamil DMA7PEW Angina pectoris BA40 Approved [41]
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [101]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [102]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [103]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [104]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [105]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [105]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [106]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [107]
Capsaicin DMGMF6V Back pain ME84.Z Approved [108]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [109]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [42]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [43]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [44]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [45]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [46]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [47]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [39]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [48]
Verapamil DMA7PEW Angina pectoris BA40 Approved [49]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2A6 (CYP2A6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [42]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [8]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [51]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [37]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [8]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [52]
Metronidazole DMTIVEN Abscess Approved [53]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [54]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [55]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [56]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [57]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [58]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [37]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [41]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [59]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [60]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [61]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [62]
Propranolol DM79NTF Angina pectoris BA40 Approved [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [64]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [65]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [66]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [10]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [67]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [68]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [69]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [70]
Verapamil DMA7PEW Angina pectoris BA40 Approved [71]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [10]
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [101]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [102]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [107]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [107]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [110]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [111]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [112]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [113]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [114]
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [115]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [72]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [10]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [10]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [10]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [8]
Verapamil DMA7PEW Angina pectoris BA40 Approved [73]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [10]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [10]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [10]
Metronidazole DMTIVEN Abscess Approved [53]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C18 (CYP2C18)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [8]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [74]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [54]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [8]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [75]
Diazepam DM08E9O Alcohol withdrawal Approved [76]
Methadone DMTW6IU Advanced cancer 2A00-2F9Z Approved [77]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [78]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [79]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [80]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [42]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [81]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [81]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [8]
Verapamil DMA7PEW Angina pectoris BA40 Approved [82]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [83]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [84]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [81]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [85]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [86]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [87]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [88]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [8]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [89]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [8]
Verapamil DMA7PEW Angina pectoris BA40 Approved [90]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [91]
Estrone DM5T6US Acne vulgaris ED80 Approved [92]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [93]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2B6 (CYP2B6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [94]
Verapamil DMA7PEW Angina pectoris BA40 Approved [8]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [95]
Estrone DM5T6US Acne vulgaris ED80 Approved [88]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [11]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [96]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [97]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [98]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [99]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [100]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [116]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [117]
Panobinostat DM58WKG Chronic graft versus host disease Approved [118]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [13]
Testosterone DM7HUNW Hot flushes GA30 Approved [119]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [119]
Leflunomide DMR8ONJ Arthritis FA20 Approved [120]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [116]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [114]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [121]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By C-reactive protein (CRP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [122]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [123]
Quercetin DM3NC4M Obesity 5B81 Approved [124]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [125]
Acalabrutinib DM7GCVW leukaemia 2A60-2B33 Approved [126]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [127]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [128]
Tibolone DM78XFG Anabolic metabolism 5C50-5C8Z Approved [129]
Testosterone DM7HUNW Hot flushes GA30 Approved [130]
Milrinone DM8TUPF Congestive heart failure BD10 Approved [131]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [132]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [133]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [114]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [134]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [135]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [136]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [137]
Arsenic DMTL2Y1 N. A. N. A. Approved [138]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [12]
Tamibarotene DM3G74J T-cell leukaemia 2A90 Phase 3 [133]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Paricalcitol DMYBV3G Hyperparathyroidism 5A51 Approved [12]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [139]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [140]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [141]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [142]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [114]
Isoproterenol DMK7MEY Atrioventricular block Approved [143]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [144]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [145]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [146]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Estrogen receptor (ESR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [147]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [148]
Gefitinib DM15F0X Colon adenocarcinoma Approved [149]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [150]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [151]
Liraglutide DM3FXPS Non-insulin dependent diabetes 5A11 Approved [152]
Quercetin DM3NC4M Obesity 5B81 Approved [153]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [154]
Procaine DM4LSNE Anaesthesia 9A78.6 Approved [150]
Estrone DM5T6US Acne vulgaris ED80 Approved [155]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [156]
Vidarabine DM0N85H Hepatosplenic T-cell lymphoma Approved [156]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [157]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [158]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [159]
Etidronic acid DM1XHYJ Bone Paget disease Approved [156]
Tiaprofenic acid DM23D7J Osteoarthritis FA00-FA05 Approved [156]
Bromperidol DM24XYQ Schizophrenia 6A20 Approved [156]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [160]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [161]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Kininogen-1 (KNG1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [116]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [113]
Mepyramine DMB4SFH Allergic rhinitis CA08.0 Approved [162]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [114]
Perindopril DMOPZDT Hypertension BA00-BA04 Approved [163]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [121]
Olanzapine DMPFN6Y Bipolar depression Approved [164]
Indomethacin DMSC4A7 Bursitis Approved [162]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [165]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [166]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Beta-nerve growth factor (NGF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [167]
Methotrexate DM2TEOL Anterior urethra cancer Approved [168]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [169]
MCI-186 DM8ZHP1 Amyotrophic lateral sclerosis 8B60.0 Approved [170]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [171]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [172]
Heroin diacetylmorphine DMDBWHY Neurological disorder 6B60 Approved [173]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [174]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [175]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [132]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-6 (IL6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [176]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [177]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [178]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [179]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [180]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [181]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [182]
Imiquimod DM1TMA3 Alopecia areata ED70.2 Approved [183]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [184]
Methotrexate DM2TEOL Anterior urethra cancer Approved [176]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [185]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [186]
Quercetin DM3NC4M Obesity 5B81 Approved [187]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [188]
Panobinostat DM58WKG Chronic graft versus host disease Approved [118]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [189]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [190]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [134]
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [191]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [132]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [13]
Quercetin DM3NC4M Obesity 5B81 Approved [116]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [117]
Panobinostat DM58WKG Chronic graft versus host disease Approved [118]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [13]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [13]
Testosterone DM7HUNW Hot flushes GA30 Approved [119]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [119]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [113]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [114]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Caspase-3 (CASP3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [192]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [193]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [194]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [195]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [196]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [197]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [198]
Mannitol DMSCDY9 Bronchiectasis CA24 Approved [199]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [200]
Aprepitant DM053KT Depression 6A70-6A7Z Approved [201]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Caspase-9 (CASP9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [202]
Mannitol DMSCDY9 Bronchiectasis CA24 Approved [203]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [178]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [204]
Leuprorelin acetate DM15HAT Prostate cancer 2C82.0 Approved [205]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [206]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [207]
Meloxicam DM2AR7L Arthritis FA20 Approved [208]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [209]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [210]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metoclopramide DMFA5MY Nausea MD90 Approved [211]
Quinidine DMLPICK N. A. N. A. Approved [212]
Verapamil DMA7PEW Angina pectoris BA40 Approved [213]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [214]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [214]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [215]
Propranolol DM79NTF Angina pectoris BA40 Approved [216]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [217]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [218]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [214]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Neuronatin (NNAT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [188]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [219]
Ethanol DMDRQZU Chronic pain MG30 Approved [220]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [221]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [222]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [223]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [132]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [224]
THAPSIGARGIN DMDMQIE N. A. N. A. Preclinical [225]
ELLAGIC ACID DMX8BS5 Discovery agent N.A. Investigative [226]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [227]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [228]
Quercetin DM3NC4M Obesity 5B81 Approved [116]
Leflunomide DMR8ONJ Arthritis FA20 Approved [120]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [113]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [229]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [190]
Menthol DMG2KW7 Back pain ME84.Z Approved [230]
Capsaicin DMGMF6V Back pain ME84.Z Approved [231]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [232]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sulfotransferase 1A1 (SULT1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [166]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [233]
Minoxidil DMA2Z4F Alopecia ED70 Approved [234]
Benzyl alcohol DMBVYDI Head and body lice 1G00.0 Approved [235]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [234]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [236]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [139]
Methotrexate DM2TEOL Anterior urethra cancer Approved [237]
Quercetin DM3NC4M Obesity 5B81 Approved [116]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [117]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Histamine H1 receptor (HRH1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Desloratadine DM56YN7 Allergic rhinitis CA08.0 Approved [106]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [106]
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [12]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [185]
Methotrexate DM2TEOL Anterior urethra cancer Approved [168]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [238]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [113]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [114]
Clozapine DMFC71L Schizophrenia 6A20 Approved [239]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [221]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [240]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [241]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [242]
Etretinate DM2CZFA Keratosis ED56 Approved [243]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [244]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [245]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [246]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [247]
Quercetin DM3NC4M Obesity 5B81 Approved [116]
Furazolidone DM3P6V7 Diarrhea ME05.1 Approved [248]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [12]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [249]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [250]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [251]
Meloxicam DM2AR7L Arthritis FA20 Approved [252]
Quercetin DM3NC4M Obesity 5B81 Approved [253]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [254]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [255]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [224]
Retigabine DMGNYIH Behcet disease 4A62 Approved [256]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sulfotransferase 1B1 (SULT1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Benzyl alcohol DMBVYDI Head and body lice 1G00.0 Approved [235]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [166]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [257]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [258]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [114]
Chenodiol DMQ8JIK Cholelithiasis DC11 Approved [259]
Arsenic DMTL2Y1 N. A. N. A. Approved [260]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [261]
Diethylstilbestrol DMN3UXQ Gonorrheal vaginitis GA02 Approved [262]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [262]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.9 (SCN11A) TTN9VTF SCNBA_HUMAN Blocker [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [8]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [8]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [11]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [8]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [10]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alkaline phosphatase, placental type (ALPP) OTZU4G9W PPB1_HUMAN Drug Response [12]
Alpha-1-acid glycoprotein 1 (ORM1) OTZKSBRE A1AG1_HUMAN Protein Interaction/Cellular Processes [13]
Alpha-1-acid glycoprotein 2 (ORM2) OTRJGZP8 A1AG2_HUMAN Protein Interaction/Cellular Processes [13]
Beta-nerve growth factor (NGF) OTOLABJT NGF_HUMAN Gene/Protein Processing [14]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Drug Response [12]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [15]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Gene/Protein Processing [15]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Biotransformations [16]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Biotransformations [17]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Drug Response [12]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2623).
2 Lidocaine FDA Label
3 ClinicalTrials.gov (NCT00651313) Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods). U.S. National Institutes of Health.
4 Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
5 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
6 Pharmacokinetics of lidocaine hydrochloride metabolized by CYP3A4 in Chinese Han volunteers living at low altitude and in native Han and Tibetan Chinese volunteers living at high altitude. Pharmacology. 2016;97(3-4):107-13.
7 Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000 Aug;28(8):959-65.
8 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
9 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
10 Drug Interactions Flockhart Table
11 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
12 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
13 Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. doi: 10.1097/00008571-199610000-00004.
14 Lidocaine prevents breast cancer growth by targeting neuronatin to inhibit nerve fibers formation. J Toxicol Sci. 2021;46(7):329-339. doi: 10.2131/jts.46.329.
15 Apoptosis and mitochondrial dysfunction in human chondrocytes following exposure to lidocaine, bupivacaine, and ropivacaine. J Bone Joint Surg Am. 2010 Mar;92(3):609-18. doi: 10.2106/JBJS.H.01847.
16 The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor. Eur J Clin Pharmacol. 2005 Jun;61(4):247-56.
17 Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos. 2004 Dec;32(12):1434-45. doi: 10.1124/dmd.104.001313. Epub 2004 Sep 21.
18 The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
19 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
20 Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
21 Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
22 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
23 Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
24 Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
25 Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76.
26 Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
27 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
28 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
29 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
30 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
31 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
32 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
33 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
34 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
35 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
36 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
37 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
38 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
39 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
40 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
41 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
42 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
43 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
44 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
45 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
46 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
47 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
48 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
49 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
50 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
51 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
52 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
53 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
54 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
55 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
56 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
57 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
58 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
59 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
60 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
61 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
62 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
63 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
64 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
65 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
66 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
67 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
68 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
69 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
70 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
71 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
72 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
73 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
74 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
75 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
76 Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
77 Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
78 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
79 Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
80 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
81 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
82 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
83 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
84 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
85 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
86 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
87 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
88 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
89 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
90 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
91 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
92 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
93 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
94 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
95 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
96 Drugs that may have potential CYP2B6 interactions.
97 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
98 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
99 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
100 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
101 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
102 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
103 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
104 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
105 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
106 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
107 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
108 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
109 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
110 Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
111 Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
112 Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 2017;42(3):343-348.
113 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
114 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
115 Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.
116 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
117 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
118 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
119 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
120 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
121 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
122 C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS. 2004 Dec 3;18(18):2434-7.
123 Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004 Aug;44(2):180-5. doi: 10.1161/01.HYP.0000133310.42762.25. Epub 2004 Jun 7.
124 The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol. 2007 Feb 28;557(2-3):221-9.
125 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
126 Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020 Jun 5;5(48):eabd0110. doi: 10.1126/sciimmunol.abd0110. Epub 2020 Jun 5.
127 The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Curr Med Res Opin. 1975;3(5):286-97. doi: 10.1185/03007997509114779.
128 Intractable insomnia after cessation of treatment with thalidomide. Gastroenterology. 2001 May;120(6):1567-8. doi: 10.1053/gast.2001.24495.
129 Effects of hormone treatment on hemostasis variables. Climacteric. 2007 Oct;10 Suppl 2:32-7. doi: 10.1080/13697130701598548.
130 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
131 The efficacy of preemptive Milrinone or Amrinone therapy in patients undergoing coronary artery bypass grafting. Anesth Analg. 2002 Jan;94(1):22-30, table of contents. doi: 10.1097/00000539-200201000-00005.
132 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
133 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
134 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
135 Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
136 The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
137 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
138 Gene expression levels in normal human lymphoblasts with variable sensitivities to arsenite: identification of GGT1 and NFKBIE expression levels as possible biomarkers of susceptibility. Toxicol Appl Pharmacol. 2008 Jan 15;226(2):199-205. doi: 10.1016/j.taap.2007.09.004. Epub 2007 Sep 15.
139 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
140 Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
141 Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
142 The psychoactive compound of Cannabis sativa, (9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover. Toxicology. 2015 Aug 6;334:94-103. doi: 10.1016/j.tox.2015.06.005. Epub 2015 Jun 9.
143 The effects of desmethylimipramine on cyclic AMP-stimulated gene transcription in a model cell system. Biochem Pharmacol. 2005 Sep 1;70(5):762-9. doi: 10.1016/j.bcp.2005.06.012.
144 The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
145 Ornithine decarboxylase antizyme upregulates DNA-dependent protein kinase and enhances the nonhomologous end-joining repair of DNA double-strand breaks in human oral cancer cells. Biochemistry. 2007 Aug 7;46(31):8920-32. doi: 10.1021/bi7000328. Epub 2007 Jul 14.
146 Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
147 Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003 Jun;144(6):2425-36. doi: 10.1210/en.2002-221054.
148 Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
149 Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
150 Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
151 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
152 Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
153 Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol. 2001 Sep;60(3):595-602.
154 Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer. 2007 Apr 23;96(8):1204-15. doi: 10.1038/sj.bjc.6603705. Epub 2007 Mar 27.
155 Prediction of the combined effects of multiple estrogenic chemicals on MCF-7 human breast cancer cells and a preliminary molecular exploration of the estrogenic proliferative effects and related gene expression. Ecotoxicol Environ Saf. 2018 Sep 30;160:1-9. doi: 10.1016/j.ecoenv.2018.05.025. Epub 2018 May 21.
156 Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
157 Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
158 Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
159 Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
160 Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
161 Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
162 Effects of capsaicin, bradykinin and prostaglandin E2 in the human skin. Br J Dermatol. 1992 Feb;126(2):111-7. doi: 10.1111/j.1365-2133.1992.tb07806.x.
163 Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J Pharmacol. 2002 Jan;88(1):100-7. doi: 10.1254/jjp.88.100.
164 Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia. Proteomics Clin Appl. 2015 Oct;9(9-10):907-16. doi: 10.1002/prca.201400148. Epub 2015 May 15.
165 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
166 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
167 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
168 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
169 Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal. 2003 Sep;15(9):851-9. doi: 10.1016/s0898-6568(03)00036-6.
170 Edaravone improves the expression of nerve growth factor in human astrocytes subjected to hypoxia/reoxygenation. Neurosci Res. 2010 Mar;66(3):284-9. doi: 10.1016/j.neures.2009.11.011. Epub 2009 Nov 30.
171 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
172 Exposure to nerve growth factor worsens nephrotoxic effect induced by Cyclosporine A in HK-2 cells. PLoS One. 2013 Nov 7;8(11):e80113. doi: 10.1371/journal.pone.0080113. eCollection 2013.
173 Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. J Psychopharmacol. 2007 Nov;21(8):820-5. doi: 10.1177/0269881107078491. Epub 2007 Aug 22.
174 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
175 Dexamethasone and the inflammatory response in explants of human omental adipose tissue. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):292-8.
176 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
177 Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. Eur J Cancer. 2010 Jul;46(10):1848-55. doi: 10.1016/j.ejca.2010.03.026. Epub 2010 Apr 17.
178 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
179 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
180 Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
181 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
182 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
183 (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
184 Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
185 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
186 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
187 Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
188 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
189 Valproate reversibly reduces neurite outgrowth by human SY5Y neuroblastoma cells. Brain Res. 2009 Dec 11;1302:21-33. doi: 10.1016/j.brainres.2009.09.051. Epub 2009 Sep 18.
190 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
191 Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
192 Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
193 [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
194 Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
195 Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
196 Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
197 Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
198 Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
199 Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
200 mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
201 Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
202 Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003 Sep;144(9):3852-9. doi: 10.1210/en.2003-0098.
203 Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J Biol Chem. 2002 Jul 26;277(30):27393-400. doi: 10.1074/jbc.M201963200. Epub 2002 May 14.
204 Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
205 Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
206 The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res. 2010 Jul;91(1):15-25.
207 Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
208 Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. J Biochem Mol Toxicol. 2022 Nov;36(11):e23185. doi: 10.1002/jbt.23185. Epub 2022 Aug 3.
209 Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002 Feb 1;86(3):443-8. doi: 10.1038/sj.bjc.6600079.
210 Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
211 Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
212 Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
213 Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
214 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
215 Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
216 Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
217 Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
218 Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
219 Effects of valproic acid on gene expression during human embryonic stem cell differentiation into neurons. J Toxicol Sci. 2014 Jun;39(3):383-90. doi: 10.2131/jts.39.383.
220 Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
221 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
222 Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
223 High expressions of neuronatin isoforms in favorable neuroblastoma. J Pediatr Hematol Oncol. 2007 Aug;29(8):551-6. doi: 10.1097/MPH.0b013e3181256b7b.
224 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
225 Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
226 Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci. 2002 Mar 1;70(15):1821-39.
227 Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001 Oct;134(4):845-52. doi: 10.1038/sj.bjp.0704327.
228 Comparison of protective effect of ascorbic acid on redox and endocannabinoid systems interactions in in vitro cultured human skin fibroblasts exposed to UV radiation and hydrogen peroxide. Arch Dermatol Res. 2017 May;309(4):285-303. doi: 10.1007/s00403-017-1729-0. Epub 2017 Mar 11.
229 Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
230 The anthelminthic drug praziquantel is a selective agonist of the sensory transient receptor potential melastatin type 8 channel. Toxicol Appl Pharmacol. 2017 Dec 1;336:55-65. doi: 10.1016/j.taap.2017.10.012. Epub 2017 Oct 18.
231 Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol. 2004 Mar;13(3):129-39. doi: 10.1111/j.0906-6705.2004.0178.x.
232 Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells. Arch Toxicol. 2018 Apr;92(4):1507-1524.
233 Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
234 Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms. Drug Metab Dispos. 2001 Mar;29(3):274-81.
235 Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
236 Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
237 Methotrexate induction of human sulfotransferases in Hep G2 and Caco-2 cells. J Appl Toxicol. 2005 Sep-Oct;25(5):354-60.
238 Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
239 No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
240 Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
241 Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
242 K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro. 2012 Apr;26(3):429-34. doi: 10.1016/j.tiv.2012.01.013. Epub 2012 Jan 17.
243 Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
244 High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol. 2017 Mar;91(3):1367-1383. doi: 10.1007/s00204-016-1781-0. Epub 2016 Jun 29.
245 Enhanced GRP78 protein expression via the IRE1/ASK1/p38 MAPK pathway during As(2)O(3)-induced endoplasmic reticulum stress in BEAS-2B cells. Toxicology. 2021 Oct;462:152962. doi: 10.1016/j.tox.2021.152962. Epub 2021 Sep 21.
246 [Simvastatin-induced apoptosis of K562 cells is mediated by endoplasmic reticulum stress]. Yao Xue Xue Bao. 2008 Apr;43(4):371-7.
247 Chronic oxycodone induces integrated stress response in rat brain. BMC Neurosci. 2015 Sep 16;16:58. doi: 10.1186/s12868-015-0197-8.
248 Involvement of the activation of Nrf2/HO-1, p38 MAPK signaling pathways and endoplasmic reticulum stress in furazolidone induced cytotoxicity and S phase arrest in human hepatocyte L02 cells: modulation of curcumin. Toxicol Mech Methods. 2017 Mar;27(3):165-172. doi: 10.1080/15376516.2016.1273424. Epub 2017 Jan 8.
249 Ethnic-Related Sodium Voltage-Gated Channel Subunit 5 Polymorphisms Shape the In Vitro Pharmacological Action of Amiodarone upon Na(v)1.5. Mol Pharmacol. 2021 Jun;99(6):448-459. doi: 10.1124/molpharm.120.000176. Epub 2021 Apr 6.
250 Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol. 2003 Jan;26(1P2):338-41. doi: 10.1046/j.1460-9592.2003.00045.x.
251 Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi: 10.1074/jbc.RA118.004929. Epub 2018 Sep 14.
252 Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. Chem Biol Interact. 2021 Apr 1;338:109425. doi: 10.1016/j.cbi.2021.109425. Epub 2021 Feb 19.
253 Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
254 Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
255 Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2016 Apr 1;296:42-53. doi: 10.1016/j.taap.2016.01.015. Epub 2016 Jan 25.
256 Modulation of the heart's electrical properties by the anticonvulsant drug retigabine. Toxicol Appl Pharmacol. 2017 Aug 15;329:309-317. doi: 10.1016/j.taap.2017.06.018. Epub 2017 Jun 20.
257 Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.
258 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
259 Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. Life Sci. 2016 Jul 1;156:47-56.
260 Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. Epigenetics. 2014 May;9(5):774-82. doi: 10.4161/epi.28153. Epub 2014 Feb 13.
261 Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
262 Sulfation of environmental estrogen-like chemicals by human cytosolic sulfotransferases. Biochem Biophys Res Commun. 2000 Jan 7;267(1):80-4. doi: 10.1006/bbrc.1999.1935.